List view / Grid view
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.
11 June 2015 | By Victoria White
LDC and Johnson & Johnson Innovation will collaborate to identify and accelerate innovative drug candidates for diseases with high unmet medical needs...
11 June 2015 | By Victoria White
ModiQuest has discovered the cellular mechanism of action of its tACPA for the treatment of rheumatoid arthritis (RA) and other diseases...
10 June 2015 | By Victoria White
A previously unknown link between the immune system and the death of motor neurons in amyotrophic lateral sclerosis has been discovered by scientists...
10 June 2015 | By Drug Target Review
Included in this issue: Drug Discovery, Screening, Hit-to-Lead, Antibodies, Stem Cells, Kinases and much more...
10 June 2015 | By Kenji Schorpp, Kamyar Hadian, Sheraz Gul, Horst Flotow
This Stem Cells In-Depth Focus features articles on stem cell-derived cardiomyocytes, and their use in drug discovery and development, as well as a look at how venom could be used in stem cell differentiation...
10 June 2015 | By Kenji Schorpp, Kamyar Hadian, Sheraz Gul, Horst Flotow
In this Screening In-Depth Focus, high throughput screening is the topic focused on by Kenji Schorpp and Kamyar Hadian, Institute of Molecular Toxicology and Pharmacology, and Sheraz Gul, Fraunhofer Institute for Molecular Biology and Applied Ecology. They discuss the importance of the technique in drug discovery today as well as…
Dementia is a global crisis with 76 million people worldwide expected to be living with the condition by 2030. Current symptomatic treatments provide modest improvements in cognition but disease-modifying therapies for diseases like Alzheimer’s – the most common cause of dementia – do not yet exist.
10 June 2015 | By IntelliCyt Corporation
The immune system plays a vital role in keeping us alive but also participates in many diseases adversely affecting quality of life across the globe. It can be over activated, leading to a variety of inflammation and autoimmune diseases, or suppressed, leading to a vast array of diseases from AIDS…
Academia and pharma have always been uneasy bedfellows. There has in the past been tension between both caused by a range of issues that neither party was willing to try and resolve. However, there is a new impetus to solve these issues as both parties have started to realise that…
From the beginning of time in the drug discovery world, the integration of disciplines has driven the identification of new lead molecules. Chemists, pharmacologists and biologists work together to understand a disease state and how to perturb that state back towards a normal healthy condition. However, in the early days…
Monoclonal antibodies have come of age as therapeutics; there are now more than 30 antibodies on the market and over 200 in clinical trials. The attractions of therapeutic antibodies lie not only in their potential to make potent drugs but also their relative low risk in comparison to small molecule…
9 June 2015 | By Victoria White
Scientists have discovered that a toxin secreted by Vibrio vulnificus has potential to prevent the growth of tumours by cutting the protein Ras...
8 June 2015 | By Select Biosciences
Select Biosciences is delighted to announce that its Organ-on-a-Chip and 3D-Printing in the Life Sciences Conference, Boston, July 8-9, 2015 features all the international key opinion leaders in the organ-on-a-chip/body-on-a-chip field as well as 3D-bioprinting fields...
8 June 2015 | By Victoria White
A $10 billion market exists for a company able to develop a novel, targeted opioid therapy that excludes side effects such as addiction and constipation...
3 June 2015 | By Victoria White
Auspherix has raised £6 million in a Series A venture financing and is establishing operations on the Stevenage Bioscience Catalyst site...
